SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a positive analyst upgrade that highlights the company's progress in regulatory pathways and validates the therapeutic potential of its lead candidate, Sonelokimab. Investors are actively discussing the stock's significant long-term growth prospects, the potential for a strategic buyout, and the upcoming clinical data readouts that are expected to solidify the drug's position as a best-in-class treatment.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is trending as investors closely monitor the development of Project Matador and anticipate a potential tenant announcement, following reports of a substantial equipment financing facility and strategic partnerships. The community remains actively divided, with many debating the company's timeline for operational capacity and power grid integration, while others highlight the massive short interest and potential for a significant upside breakout once a definitive data center tenant is secured.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium is seeing heightened trading activity as the company's recent operational updates and offtake agreements drive significant investor interest, leading to strong buying momentum in the stock. The community is actively debating the stock's potential for a breakout, with many discussing the impact of lithium supply-demand dynamics and monitoring insider buying as a key indicator of confidence in future growth.

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

United Therapeutics is trending following the TETON-1 study's success in meeting its primary efficacy endpoint for treating idiopathic pulmonary fibrosis, driving investor optimism regarding the company's pipeline expansion. The community is actively discussing the drug's potential market impact, the competitive landscape involving inhaled treprostinil treatments, and broader implications for the company's valuation as it maintains its strong commercial presence.

Americas Gold & Silver Corp. engages in the acquisition, exploration, development, and exploration of mineral resource properties. It operates through the following segments: Cosalá Operations, Galena Complex, Relief Canyon, and Corporate and Other. The Cosalá Operations segment operates in Mexico. The Galena Complex and Relief Canyon segments focuses on the United States. The company was founded by Peter Jude Hawley on May 12, 1998 and is headquartered in Toronto, Canada.

Americas Gold and Silver Corp

Americas Gold and Silver Corporation

Americas Gold and Silver is trending as investors monitor the company's recent acquisition of the Crescent Silver Mine and its strategic positioning in the domestic antimony market. Market participants are actively discussing the stock's high institutional ownership and potential for rapid growth as the company aims to quadruple silver production while benefiting from record-high precious metal prices.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is facing intense scrutiny following the release of elegrobart REVEAL-1 phase 3 data, which triggered a significant pre-market stock decline despite meeting primary endpoints. Investors are actively debating the drug's competitive positioning against current standard-of-care treatments, with community sentiment divided between those viewing the pullback as a buying opportunity and skeptics questioning its long-term viability without head-to-head trial data.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently trading near multi-year lows, fueling intense debate among retail traders regarding whether the stock is an oversold value opportunity ahead of earnings or a value trap facing structural headwinds in China. While some investors are pointing to insider buying and historical support levels as a signal to accumulate, others remain skeptical, citing ongoing inventory issues, declining margins, and stiff competition from newer athletic brands.

Roma Green Finance Ltd. is a holding company, which engages in the provision of environmental, social and governance, sustainability, and climate change related advisory services through its subsidiaries. Its services include corporate and risk advisory, sustainability strategy services, climate risk advisory, ESG reporting services, and sustainable finance. The company was founded in 2018 and is headquartered in Hong Kong.

Roma Green Finance Ltd - Ordinary Shares - Class A

Roma Green Finance Ltd

Roma Green Finance is trending following the board's authorization of a 100 million dollar share repurchase program, sparking intense community debate over its potential to boost shareholder value versus concerns about the company's long-term financial health. Traders are closely monitoring the stock's significant volatility and trading volume, with many actively discussing whether the buyback will support a sustained upward trend or if the stock remains vulnerable to typical small-cap pump-and-dump dynamics.

Alaska Air Group, Inc. is a holding company, which engages in the provision of air transportation services. It operates through the following segments: Alaska Airlines, Hawaiian Airlines, and Regional. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo. The Hawaiian Airlines segment refers to scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. The Regional segment consists of Horizon's and other third-party carriers’ scheduled air transportation on E175 aircraft for passengers under CPAs. The company was founded in 1985 and is headquartered in Seattle, WA.

Alaska Air Group Inc.

Alaska Air is trending as investors digest the airline's latest quarterly results and guidance, with the market focused on its aggressive growth strategy and integration of Hawaiian Airlines. Community sentiment remains largely bullish, highlighting strong demand, operational efficiency, and a significant share buyback plan that continues to drive positive momentum.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific (BSX) is trending following positive data from the Champion-AF clinical trial, which confirmed the safety and efficacy of the Watchman FLX device compared to standard anticoagulants. Community discourse remains highly active, balancing excitement over the company's clinical innovation with skepticism driven by ongoing litigation, recent analyst price target adjustments, and the broader macro-driven rotation within the medtech sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of "Moderate Buy" from Brokerages

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twenty-one ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating...

Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report?

Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

E. Ohman J or Asset Management AB Has $23.06 Million Stock Holdings in Cytokinetics, Incorporated $CYTK

E. Ohman J or Asset Management AB lowered its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 10.8% during the fourth quarter, according to its most recent filing with...

Cytokinetics, Incorporated $CYTK Shares Bought by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP lifted its position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 15.4% during the 3rd quarter, according to its most recent filing with the...

Cytokinetics (NASDAQ:CYTK) EVP Sells $530,885.30 in Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 8,542 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $62.15, for a total value of $530,885.30. Following the completion of the sale, the executive vice president...

Sung Lee Sells 4,935 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Sung Lee sold 4,935 shares of the stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total transaction of $306,710.25. Following the sale, the executive vice president directly...

Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells 1,930 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 1,930 shares of the firm's stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $62.07, for a total value of $119,795.10. Following the completion of the sale, the executive vice...

Andrew Callos Sells 8,542 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 8,542 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total transaction of $530,885.30. Following the completion of the sale, the...

Fady Ibraham Malik Sells 12,033 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 12,033 shares of Cytokinetics stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total value of $747,850.95. Following the sale, the executive...

Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells 36,601 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) CEO Robert Blum sold 36,601 shares of the firm's stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $62.15, for a total transaction of $2,274,752.15. Following the sale, the chief executive officer...

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Cytokinetics Inc

Fred Wilson - Union Square Ventures

Abigail Johnson - Fidelity

Jim Cramer - Media Personality

Josh Brown - Ritholtz Wealth Management

A lifetime achievement for industry titans. This honor is reserved for an individual whose groundbreaking contributions have shaped the investing landscape and how we engage with the markets.

Current Price	$62.50
Prev Close	$63.48
Open	$63.44
Dividend Yield	0.00%
50-Day Moving Average	$63.53
Beta	0.91
Avg. Volume	1.86M
PE Ratio	-9.57

52-Week High	$70.98
52-Week Low	$29.31
Market Capitalization	$7.7B
EPS (Annual)	-$6.54
Price to Book	-11.65
Revenue Per Employee	$130,815.75

CYTK
Cytokinetics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CYTK News

CYTKCytokinetics Inc